Literature DB >> 19508171

The role of fibroblast growth factors in tumor growth.

M Korc1, R E Friesel.   

Abstract

Biological processes that drive cell growth are exciting targets for cancer therapy. The fibroblast growth factor (FGF) signaling network plays a ubiquitous role in normal cell growth, survival, differentiation, and angiogenesis, but has also been implicated in tumor development. Elucidation of the roles and relationships within the diverse FGF family and of their links to tumor growth and progression will be critical in designing new drug therapies to target FGF receptor (FGFR) pathways. Recent studies have shown that FGF can act synergistically with vascular endothelial growth factor (VEGF) to amplify tumor angiogenesis, highlighting that targeting of both the FGF and VEGF pathways may be more efficient in suppressing tumor growth and angiogenesis than targeting either factor alone. In addition, through inducing tumor cell survival, FGF has the potential to overcome chemotherapy resistance highlighting that chemotherapy may be more effective when used in combination with FGF inhibitor therapy. Furthermore, FGFRs have variable activity in promoting angiogenesis, with the FGFR-1 subgroup being associated with tumor progression and the FGFR-2 subgroup being associated with either early tumor development or decreased tumor progression. This review highlights the growing knowledge of FGFs in tumor cell growth and survival, including an overview of FGF intracellular signaling pathways, the role of FGFs in angiogenesis, patterns of FGF and FGFR expression in various tumor types, and the role of FGFs in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19508171      PMCID: PMC3664927          DOI: 10.2174/156800909789057006

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  142 in total

1.  FGFR-2 and -3 play an important role in initial stages of oral oncogenesis.

Authors:  Eleftherios Vairaktaris; Vassilis Ragos; Christos Yapijakis; Spyridoula Derka; Stavros Vassiliou; Emeka Nkenke; Athanassios Yannopoulos; Sofia Spyridonidou; Antonis Vylliotis; Veronica Papakosta; Sofia Loukeri; Andreas Lazaris; Christina Tesseromatis; Christos Tsigris; Efstratios Patsouris
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

2.  Coordinate loss of fibroblast growth factor 2 and laminin 5 expression during neoplastic progression of mammary duct epithelium.

Authors:  Reju Korah; Kasturi Das; Michael E Lindy; Meera Hameed; Robert Wieder
Journal:  Hum Pathol       Date:  2006-09-25       Impact factor: 3.466

3.  Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis.

Authors:  Xinqiang Huang; Chundong Yu; Chengliu Jin; Chaofeng Yang; Rui Xie; Dongdong Cao; Fen Wang; Wallace L McKeehan
Journal:  Mol Carcinog       Date:  2006-12       Impact factor: 4.784

4.  The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development.

Authors:  Richard Grose; Vera Fantl; Sabine Werner; Athina-Myrto Chioni; Monika Jarosz; Robert Rudling; Barbara Cross; Ian R Hart; Clive Dickson
Journal:  EMBO J       Date:  2007-02-15       Impact factor: 11.598

5.  Effects of some beta-adrenoceptor antagonists on orthostatic hypotension in repeatedly cold- (SART-) stressed rats.

Authors:  Yoshinori Funakami; Taeko Hata; Eiji Itoh; Seigo Itano
Journal:  Biol Pharm Bull       Date:  2007-02       Impact factor: 2.233

6.  Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells.

Authors:  Allison B Moffa; Stephen P Ethier
Journal:  J Cell Physiol       Date:  2007-03       Impact factor: 6.384

7.  Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization.

Authors:  Satoshi Tsunoda; Toshiyuki Nakamura; Hiroaki Sakurai; Ikuo Saiki
Journal:  Cancer Sci       Date:  2007-03-14       Impact factor: 6.716

8.  Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions.

Authors:  M Kornmann; T Ishiwata; H G Beger; M Korc
Journal:  Oncogene       Date:  1997-09-18       Impact factor: 9.867

9.  MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.

Authors:  Esther Masih-Khan; Suzanne Trudel; Carla Heise; Zhihua Li; Joshua Paterson; Vincent Nadeem; Ellen Wei; David Roodman; Jaime O Claudio; P Leif Bergsagel; A Keith Stewart
Journal:  Blood       Date:  2006-07-18       Impact factor: 22.113

10.  Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth.

Authors:  Zhanbing Liu; Nicola Neiss; Shaoxia Zhou; Doris Henne-Bruns; Murray Korc; Max Bachem; Marko Kornmann
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

View more
  114 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

Review 2.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

3.  Critical role of miR-10b in transforming growth factor-β1-induced epithelial-mesenchymal transition in breast cancer.

Authors:  Xu Han; Sun Yan; Zhang Weijie; Wang Feng; Wang Liuxing; Li Mengquan; Fan Qingxia
Journal:  Cancer Gene Ther       Date:  2014-01-24       Impact factor: 5.987

Review 4.  Current status and future prospect of FSHD region gene 1.

Authors:  Arman Kunwar Hansda; Ankit Tiwari; Manjusha Dixit
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

5.  Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

Authors:  Robert J Motzer; Camillo Porta; Nicholas J Vogelzang; Cora N Sternberg; Cezary Szczylik; Jakub Zolnierek; Christian Kollmannsberger; Sun Young Rha; Georg A Bjarnason; Bohuslav Melichar; Ugo De Giorgi; Viktor Grünwald; Ian D Davis; Jae-Lyun Lee; Emilio Esteban; Gladys Urbanowitz; Can Cai; Matthew Squires; Mahtab Marker; Michael M Shi; Bernard Escudier
Journal:  Lancet Oncol       Date:  2014-02-17       Impact factor: 41.316

6.  Sef Regulates Epithelial-Mesenchymal Transition in Breast Cancer Cells.

Authors:  Qing He; Yan Gong; Lindsey Gower; Xuehui Yang; Robert E Friesel
Journal:  J Cell Biochem       Date:  2016-03-16       Impact factor: 4.429

7.  A novel role for inducible Fut2 in angiogenesis.

Authors:  Pei-Suen Tsou; Jeffrey H Ruth; Phillip L Campbell; Takeo Isozaki; SolHee Lee; Hubert Marotte; Steven E Domino; Alisa E Koch; Mohammad A Amin
Journal:  Angiogenesis       Date:  2012-10-12       Impact factor: 9.596

8.  NMR characterization of copper and lipid interactions of the C2B domain of synaptotagmin I-relevance to the non-classical secretion of the human acidic fibroblast growth factor (hFGF-1).

Authors:  Karuppanan Muthusamy Kathir; Li Gao; Dakshinamurthy Rajalingam; Anna E Daily; Sherri Brixey; Huimin Liu; Dan Davis; Paul Adams; Igor Prudovsky; Thallapuranam Krishnaswamy Suresh Kumar
Journal:  Biochim Biophys Acta       Date:  2009-10-14

9.  Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway.

Authors:  S Kamura; Y Matsumoto; J-I Fukushi; T Fujiwara; K Iida; Y Okada; Y Iwamoto
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

10.  Lewis Y promotes growth and adhesion of ovarian carcinoma-derived RMG-I cells by upregulating growth factors.

Authors:  Feifei Li; Bei Lin; Yingying Hao; Yan Li; Juanjuan Liu; Jianping Cong; Liancheng Zhu; Qing Liu; Shulan Zhang
Journal:  Int J Mol Sci       Date:  2010-09-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.